Control Bionics (CBL.AX) Stock Price

Control Bionics Price

🇦🇺CLOSED
0.09AUD
Market closed
Today +/-
Today %

Control Bionics (CBL.AX) Stock | ISIN AU0000114183. The current Control Bionics stock price is 0.09 AUD (2026). Revenue is 14.34 M AUD. Net income is -3.91 M AUD. The P/E ratio is -6.21. Market capitalization is 37.08 M AUD. Control Bionics operates in the Health sector.

Revenue has compounded at 34.3% per year over the past 7 years to 7.04 M AUD. Control Bionics's net margin stands at -86.8%, broadly stable from -86.8% several years earlier.

Control Bionics stock price

Details

Stock Price

How to Read This Chart

This chart tracks the historical stock price of Control Bionics over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.

Total Return vs. Price Return

The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.

Intraday Price Data

When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how Control Bionics stock reacts to market openings, earnings releases, or breaking news throughout the trading session.

What to Look For

Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing Control Bionics's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.

Control Bionics Stock Price History
DateControl Bionics Price
Access this data via the Eulerpool API

Control Bionics Revenue, EBIT, Net Income

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 2018
892,400 AUD
-971,300 AUD
-972,500 AUD
Jan 1, 2019
901,400 AUD
-1.93 M AUD
-1.93 M AUD
Jan 1, 2020
3.3 M AUD
-999,800 AUD
-1.01 M AUD
Jan 1, 2021
4.09 M AUD
-3.15 M AUD
-3.55 M AUD
Jan 1, 2022
4.72 M AUD
-6.14 M AUD
-6.1 M AUD
Jan 1, 2023
5.91 M AUD
-5.21 M AUD
-5.63 M AUD
Jan 1, 2024
6.03 M AUD
-5.87 M AUD
-5.91 M AUD
Jan 1, 2025
7.04 M AUD
-5.92 M AUD
-6.11 M AUD
Invalid Date
14.34 M AUD
-1.24 M AUD
-3.91 M AUD

Control Bionics Income Statement, Balance Sheet, Cash Flow Statement

Last updated Jun 23, 2026, 1:35 AM
 
REVENUE (M AUD)
REVENUE GROWTH (%)
GROSS MARGIN (%)
GROSS INCOME (M AUD)
NET INCOME (M AUD)
NET INCOME GROWTH (%)
SHARES (M)
DOCUMENTS
20192020202120222023202420252026e
034456714
33.33252016.67100
66.6750506066.6771.4335.71
52223455
-1-1-3-6-5-5-6-3
200100-16.6720-50
83.3383.3369.5196.57102.17162.79269.69269.69
Details

Income Statement Key Figures

Revenue and Revenue Growth

Revenue is the starting point of every income statement — it measures the total sales Control Bionics generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.

Gross Margin

Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue Control Bionics retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare Control Bionics's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.

EBIT and EBIT Margin

EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.

Net Income and Earnings Per Share (EPS)

Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.

Shares Outstanding

The total number of shares Control Bionics has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.

Analyst Estimates

The projected figures represent consensus estimates from professional analysts. Compare these forecasts against Control Bionics's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.

Control Bionics stock margins

The Control Bionics margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Control Bionics. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Control Bionics.
  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 2018
91.71 %
-108.84 %
-108.98 %
Jan 1, 2019
61.69 %
-214.24 %
-214.3 %
Jan 1, 2020
78.36 %
-30.29 %
-30.46 %
Jan 1, 2021
65.04 %
-76.96 %
-86.83 %
Jan 1, 2022
58.1 %
-130.04 %
-129.26 %
Jan 1, 2023
67.31 %
-88.28 %
-95.33 %
Jan 1, 2024
75.88 %
-97.34 %
-98.08 %
Jan 1, 2025
71.14 %
-84.1 %
-86.77 %
Invalid Date
71.14 %
-8.63 %
-27.28 %

Control Bionics Stock Revenue, EBIT, Earnings per Share

The Control Bionics earnings per share therefore indicates how much revenue Control Bionics has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.
  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue per Share
EBIT per share
Earnings per Share
Details
Date
Revenue per Share
EBIT per share
Earnings per Share
Jan 1, 2018
0.01 AUD
-0.01 AUD
-0.01 AUD
Jan 1, 2019
0.01 AUD
-0.02 AUD
-0.02 AUD
Jan 1, 2020
0.04 AUD
-0.01 AUD
-0.01 AUD
Jan 1, 2021
0.06 AUD
-0.05 AUD
-0.05 AUD
Jan 1, 2022
0.05 AUD
-0.06 AUD
-0.06 AUD
Jan 1, 2023
0.06 AUD
-0.05 AUD
-0.06 AUD
Jan 1, 2024
0.04 AUD
-0.04 AUD
-0.04 AUD
Jan 1, 2025
0.03 AUD
-0.02 AUD
-0.02 AUD
Invalid Date
0.03 AUD
-0 AUD
-0.01 AUD

Control Bionics business model & stock analysis

Control Bionics Ltd. engages in the manufacture, design, and sale of wireless wearable electromyography (EMG) based augmentative and alternative communication (AAC) technology. The company assists patients whose ability to communicate verbally or through text and social media is compromised by illnesses, such as motor neuron disease, amyotrophic lateral sclerosis, and others. Its NeuroNode technology is a wireless wearable device that detects minute signals sent from the brain to any skeletal muscle and is captured as Electromyography output. This output is then sent wirelessly through the NeuroNode to a personal computer, enabling speech and other computer-controlled functions, such as email and texting. Its core systems include NeuroNode Trilogy, NeuroNode Duo, Eye-gaze Duo, and DROVE. Its technology is integrated with eye-gaze technology, whereby the eye gaze enables a cursor to be moved on a computer screen, driven like a mouse, and the NeuroNode acts like the mouse button.

Control Bionics Segments

Control Bionics Revenue by Segment (1/2)

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Details
Date
Operating expense reimbursements
Management, development and leasing fees
Marketing
Marketing revenues
Jan 1, 2014
0 AUD
0 AUD
0 AUD
0 AUD
Jan 1, 2016
0 AUD
0 AUD
0 AUD
0 AUD
Jan 1, 2017
0 AUD
0 AUD
0 AUD
0 AUD

Control Bionics Revenue by Segment (2/2)

  • 3 Years

  • 5 Years

  • 10 Years

  • Max

Malls
All Other
Associated Centers
Community Centers
Details
Date
Malls
All Other
Associated Centers
Community Centers
Jan 1, 2014
933.74 M AUD
66.88 M AUD
41.53 M AUD
18.6 M AUD
Jan 1, 2016
928.21 M AUD
43.39 M AUD
39.26 M AUD
17.39 M AUD
Jan 1, 2017
847.98 M AUD
79.27 M AUD
0 AUD
0 AUD

Control Bionics Eulerpool Fair Value

Control Bionics historical P/E ratio, EBIT multiple, and P/S ratio

Control Bionics annual returns

Details

Annual Return

What This Chart Shows

This chart breaks down 's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.

Price Return

Price return measures the percentage change in 's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.

Dividend Return

Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.

What to Look For

Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare 's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.

Control Bionics shares outstanding

The number of shares was Control Bionics in 2025 — This indicates how many shares 269.694 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.
  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Number of stocks
Details
Date
Number of stocks
Jan 1, 2018
83.33 M base_Shares
Jan 1, 2019
83.33 M base_Shares
Jan 1, 2020
83.33 M base_Shares
Jan 1, 2021
69.51 M base_Shares
Jan 1, 2022
96.57 M base_Shares
Jan 1, 2023
102.17 M base_Shares
Jan 1, 2024
162.79 M base_Shares
Jan 1, 2025
269.69 M base_Shares
Invalid Date
269.69 M base_Shares
Price targets and forecasts for Control Bionics are not yet available.

Control Bionics shareholder structure

% Name
14.19935%
Phoenix Development Fund Ltd.
Phoenix Development Fund Ltd.
13.66463%
Nightingale Partners Pty. Ltd.
Nightingale Partners Pty. Ltd.
4.85567%
Ford (Peter Shann)
Ford (Peter Shann)
2.42742%
Chapman (Craig)
Chapman (Craig)
2.20988%
Walsh (Brian)
Walsh (Brian)
1.71099%
Scintilla Funds Management Pty Ltd.
Scintilla Funds Management Pty Ltd.
1.21371%
Hancock (Russell Kay)
Hancock (Russell Kay)
1.02813%
Loidl Family
Loidl Family
0.93456%
Phillips (Stephanie)
Phillips (Stephanie)
0.8727%
Windward Capital Pty. Ltd.
Windward Capital Pty. Ltd.

Control Bionics Executives and Management Board

TT

Mr. Todd Tyler

US Country Manager

Compensation240,246 AUD
DL

Mr. Damian Lismore

Non-Executive Independent Director

Compensation47,000 AUD
SS

Dr. Samuel Straface

Non-Executive Independent Chairman of the Board

JS

Mr. Jeremy Steele

Chief Executive Officer, Managing Director, Executive Director · since 2023

SB

Ms. Shannon Boothroyd

Chief Financial Officer

Control Bionics Supply Chain

Frequently asked questions about Control Bionics

All fundamentals and in-depth analysis of Control Bionics

Our stock analysis for Control Bionics Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Control Bionics Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.